Parkinson´s disease MedDRA version: 20.0 Level: LLT Classification code 10034007 Term: Parkinson's disease NOS System Organ Class: 100000004852
Conditions
Interventions
Product Name: (2-chloro-5-[11C]methoxy-N-(((3s,5s,7s)-3,5,7-trifluoroadamantan-1-yl)methyl) benzamide)
Product Code: [11C]SMW139
Pharmaceutical Form: Injection
Sponsors
Juha Rinne / PET Centre
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: HEALTHY VOLUNTEERS 1. Subject is between 45 and 80 years (male/female). 2. Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs. 3. Subject’s body mass index is >18 and = 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score =65 years) yes F.1.3.1 Number of subjects for this age range 10
Exclusion criteria
Exclusion criteria: HEALTHY VOLUNTEERS 1. Subject has a history of any major disease that may interfere with the investigations (especially liver and kidney disease, or uncontrolled diabetes). 2. Subject has any history of a major neurological disorder. 3. Subject has elevated likelihood for hereditary Parkinson’s disease as assessed by family history. 4. Subject has a history or evidence of psychiatric disease, especially depression. A Beck Depression Inventory score should be 500 ml), donated blood or participated in another clinical trial using investigational drug(s) within 30 days prior to the imaging day. 6. Subject is currently a user (including ‘’recreational use’’) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse. 7. Subject chronically uses anti-inflammatory medication (steroids, non-steroidal anti-inflammatory drugs (NSAID), aspirine, paracetamol, etc.), or other medication known to interact with P2X7 receptors. 8. Uncontrolled hypertension juged by the investigator. . 9. Previous repetitive use of psychotropic medication. 10. Pregnancy or lactation (only for women). 11. Administration of any investigational product within 3 months before the start of the present study. 12. Known or suspected drug, alcohol or other abuse, or positive urine drug screen which may interfere with the study objective as judged by the investigator. 13. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity as judged by the investigator. 14. Subject has a contra-indication for MRI scanning. 15. Subject suffers from claustrophobia or cannot tolerate confinement during PET or MR scanning procedures; subject cannot lie still for 90 minutes inside the PET system. 16. Subject does not understand the study procedure. 17. Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator. 18. Subject has a known allergy to xylocaine (which is be used as a local anesthetic for the placement of the arterial catheter). PARKINSON`S DISEASE PATIENTS 1. Subject has parkinsonism not caused by idiopathic Parkinson’s disease (e.g. drug-induced, metabolic disorders, encephalitis, vascular parkinsonism, atypical parkinsonian syndromes such as multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration). 2. Subject has a history of another major neurological disorder or history of significant brain lesion (e.g. tumor, stroke). 3. Subject has significant structural brain lesions on T1 or T2 MRI, unrelated to IPD. 4. Subject has a history of any major disease that may interfere with radiotracer investigations (especially severe liver and kidney disease, or uncontrolled diabetes). 5. Subject is unable to lie sufficiently still in the PET system, or has tremor with significant head movements. 6. Subject consumes excessive alcohol (average > 4 units/day) or has recreational/illicit drug use (including cannabis). 7. Subject chronically uses anti-inflammatory medication including systemic steroids. 8. Subject has known allergy to lidocaine (which may be used as a local anesthetic for the placement of the arterial catheter). 9. Uncontrolled hypertension judged by the investigator. . 10. Previous repetitive use of psychotropic medication. 11. Pregnancy or lactation (only for women). 12. Administration of any investigational product within
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Primary objective: To determine regional binding differences of [11C]SMW139 in 7 PD patients and 7 healthy volunteers. ;Secondary Objective: Secondary objectives: Brain kinetics and determination of brain P2X7R availability (VT and BPND) using [11C]SMW139 PET in 7 PD patients and 7 healthy age-matched healthy controls. Correlation between nigro-striatal P2X7R availability measured with using [11C]SMW139 PET and DAT availability measured using [18F]FE-PE2I PET in 7 PD patients and 7 healthy age-matched healthy controls.;Primary end point(s): Completion of PET imaging of patients with Parkinson´s disease and healthy controls with [11C]SMW139;Timepoint(s) of evaluation of this end point: The end point will be evaluated after all study procedures in all Parkinson´s disease patients and healthy controls have been completed. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Completion of study procedures other than PET imaging of patients with Parkinson´s disease and healthy controls with [11C]SMW139;Timepoint(s) of evaluation of this end point: The end point will be evaluated after all study procedures in all Parkinson´s disease patients and healthy controls have been completed. | — |
Countries
Finland
Outcome results
None listed